15 / 15
Page 55
conferenceseries
.com
Volume 7, Issue 5 (Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN:2161-069X
Gastroenterology 2017
November 13-14, 2017
November 13-14, 2017 | Las Vegas, USA
13
th
International Conference on
Clinical Gastroenterology, Hepatology and Endoscopy
Acase of incidentally discovered colonic extra-nodal marginal zone b-cell lymphoma of mucosa-associated
lymphoid tissue
Raja Chandra Chakinala
Westchester Medical Center, USA
M
ucosa associated lymphoid tissue (MALT) lymphoma is a distinct entity that can develop in diverse anatomical locations such
as stomach, salivary gland, lung, thyroid and breast, however, colorectal involvement is rare. We present a case of colonic MALT
lymphoma in a 62-year-old woman diagnosed after a positive test for fecal occult blood. Her past medical history is significant for
nephrolithiasis, Bell’s palsy, and vulvar intraepithelial neoplasia grade 2. The patient was asymptomatic at the time of presentation,
except for a drop in hematocrit noticed during a routine follow-up at our clinic. Colonoscopy revealed sigmoid diverticulosis
and a 10 mm polyp in the sigmoid colon. Pathological examination, immunohistochemical staining, and molecular studies were
consistent with MALT lymphoma. Upper endoscopy showed diffuse chronic active gastritis, which tested positive for Helicobacter
pylori (H.pylori) by immunohistochemical staining. She was treated for H. pylori gastritis with triple therapy. She had ongoing
follow-up at hematology and GI clinic. Repeat colonoscopy did not show tumor recurrence. There are reports of regression of the
disease after treatment for H. pylori even when such infection is absent, suggesting the possible role of other micro-organisms in
the pathogenesis of non-gastric MALT lymphoma. One case reported no lymphoma recurrence over a 3 year follow-up following
a successful endoscopic resection of colonic MALT lymphoma without disseminated disease. Another case reported a complete
resolution following 2 weeks of H. pylori eradication therapy and four cycles of rituximab. However, long-term follow-up data is
lacking, and hence periodic clinical monitoring of these patients is recommended.
lotfy_1987@hotmail.comJ Gastrointest Dig Syst 2017, 7:5 (Suppl)
DOI: 10.4172/2161-069X-C1-056